RT Journal Article
SR Electronic
T1 Patient-Centered Approach Might Effectively Tackle The Definition Of Progression In Chronic Neurological Diseases: Results From The EmBioProMS Trial In Progressive Multiple Sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.07.21262777
DO 10.1101/2021.09.07.21262777
A1 Abdelhak, Ahmed
A1 Krumbholz, Markus
A1 Senel, Makbule
A1 Havla, Joachim
A1 Zettl, Uwe K.
A1 Kleiter, Ingo
A1 Skripuletz, Thomas
A1 Stahmann, Alexander
A1 Huss, Andre
A1 Antweiler, Kai
A1 Gingele, Stefan
A1 Kowarik, Markus C.
A1 Hoshi, Muna-Miriam
A1 Hengstebeck, Sandra
A1 Friede, Tim
A1 Ludolph, Albert C.
A1 Kümpfel, Tania
A1 Ziemann, Ulf
A1 Tumani, Hayrettin
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.07.21262777.abstract
AB Background Proper identification of disability accumulation in the routine clinical care of progressive multiple sclerosis (PMS) patients is usually a challenging task. Patient-reported outcome measurements (PROMs) can provide a practical, cost-efficient, and remotely accessible tool to assess disease progression.Methods EmBioProMS is a prospective, multicentric cohort, conducted in 7 specialized MS centers in Germany. PROMs were evaluated at inclusion and compared between patients with retrospective evidence of disease progression in the last two years and those with stable disease. Patients with either primary or secondary progressive MS according to the McDonald criteria 2017 were included in the analysis, while patients with incomplete PROMs scores, MS relapses, other neurological or systemic inflammatory diseases were excluded. The disease progression was assessed using a combined outcome parameter, including EDSS score, timed 25-foot walk test, and nine-hole-peg test.Results 185 patients were included in the final analysis (SPMS, n=77; PPMS, n=108). The median age and disease duration were 55 years and 13 years, respectively. Disease progression was diagnosed in 114 of 185 patients (61.6%). BDI-II, MSIS-29, and FSMC scores were worse in patients with evidence of disease progression in the last two years. Patients with any of the included PROMs above the 90th percentile had an odds ratio of 3.8 (95% confidence interval: 1.4–10.6, P=0.01) for having progression in the last two years in a binomial regression model adjusted for age, sex, disease duration, treatment status, center effect, and Expanded Disability Status Scale (EDSS). Similar results were observed in patients with PROM scores in the 80th and 70th percentile (OR: 2.9 and 3.7, P=0.015 and 0.003, respectively).Conclusion PROMs can be a simple and effective way to detect disability worsening in a chronic neurological disease like PMS and, therefore, substantially contribute to better classification and prognostication of the disease course through objective and structural patient-doctor communication.Trial Registration German Clinical Trials Register (Deutsches Register Klinischer Studien - DRKS), DRKS00020132Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00020132Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/32478196/ https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00020132 Funding StatementEmBioProMS was supported through a research grant from the German Multiple Sclerosis Society (DMSG) Federal Association, the German MS trust, the AMSEL, and the Bavarian MS Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the Institutional Review Board at the University Hospital of Ulm (#270/12), and the local ethical committees at the University Hospitals of Tuebingen, Ludwig-Maximilians University, Rostock, and Hanover. All patients signed informed consent before participating in the trial. Study procedures were conducted in accordance with the principles of the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, Hayrettin Tumani, upon reasonable request.